{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:10:15Z","timestamp":1788635415446,"version":"build-2803163510"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>This network meta-analysis was to analyze and rank the efficacy and safety of different systemic drugs in the treatment of uremic pruritus (UP) among hemodialysis patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>PubMed, Embase, Cochrane Library, and Web of Science databases were searched from inception to 10 July 2023 for randomized controlled trials (RCTs) investigating different drugs in the treatment of UP among hemodialysis patients. Drugs including cromolyn sodium, dexchlorpheniramine, difelikefalin, gabapentin, hydroxyzine, ketotifen, melatonin, montelukast, nalbuphine, nalfurafine, nemolizumab, nicotinamide, pregabalin, sertraline, thalidomide, and placebo were assessed. Outcome measures, including pruritus relief, response, and adverse events, were analyzed. Network plots, forest plots, league tables, and the surface under the cumulative ranking (SUCRA) probabilities were depicted for each outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The network meta-analysis retrieved 22 RCTs. Gabapentin (69.74%) had the highest likelihood to be the most effective drug for pruritus relief in UP patients receiving hemodialysis, followed by cromolyn sodium and hydroxyzine. Thalidomide (60.69%) and gabapentin (58.99%) were associated with significantly more drug responses for treating UP among patients receiving hemodialysis. Patients who were treated with gabapentin (40.01%) were likely to have risks of adverse events and dizziness. Lower risks of adverse events, nausea, and diarrhea were found in patients who received cromolyn sodium and lower risks of somnolence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study suggests considering gabapentin treatment when facing a patient suffering from UP. This study provides a reference for the selection of drug therapy for UP patients receiving hemodialysis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1334944","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:44:59Z","timestamp":1712292299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of different systemic drugs in the treatment of uremic pruritus among hemodialysis patients: a network meta-analysis based on randomized clinical trials"],"prefix":"10.3389","volume":"11","author":[{"given":"Xueqian","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e21127","DOI":"10.7759\/cureus.21127","article-title":"Chronic kidney disease-associated pruritus: a glance at novel and lesser-known treatments","volume":"14","author":"Elhag","year":"2022","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12882-023-03212-3","article-title":"The effectiveness of sertraline in alleviating uremic pruritus in hemodialysis patients: a randomized clinical trial","volume":"24","author":"Elsayed","year":"2023","journal-title":"BMC Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12882-022-02838-z","article-title":"Prevalence of pruritus associated with hemodialysis and its association with sleep quality among hemodialysis patients: a multicenter study","volume":"23","author":"Daraghmeh","year":"2022","journal-title":"BMC Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e0207758","DOI":"10.1371\/journal.pone.0207758","article-title":"Prevalence of chronic kidney disease-associated pruritus, and association with sleep quality among hemodialysis patients in Pakistan","volume":"13","author":"Rehman","year":"2018","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1036072","DOI":"10.3389\/fmed.2022.1036072","article-title":"Efficacy of acupoint stimulation as a treatment for uremic pruritus: a systematic review and meta-analysis","volume":"9","author":"Lu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/tcmj.tcmj_151_20","article-title":"Western and complementary alternative medicine treatment of uremic pruritus: a literature review","volume":"33","author":"Lu","year":"2021","journal-title":"Tzu Chi Med J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2340\/00015555-3125","article-title":"Mortality of Haemodialysis patients with and without chronic itch: a follow-up study of the German epidemiological hemodialysis itch study (GEHIS)","volume":"99","author":"Grochulska","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.xkme.2020.08.011","article-title":"Self-reported pruritus and clinical, Dialysis-related, and patient-reported outcomes in hemodialysis patients","volume":"3","author":"Sukul","year":"2021","journal-title":"Kidney Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e105754","DOI":"10.5812\/aapm.105754","article-title":"The role of opioids in pain Management in Elderly Patients with chronic kidney disease: a review article","volume":"10","author":"Dolati","year":"2020","journal-title":"Anesth Pain Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"28391","DOI":"10.1177\/2054358119828391","article-title":"A review of Cannabis in chronic kidney disease symptom management","volume":"6","author":"Ho","year":"2019","journal-title":"Can J Kidney Health Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1684\/ejd.2018.3356","article-title":"Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial","volume":"28","author":"Gobo-Oliveira","year":"2018","journal-title":"Eur J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jaad.2023.03.051","article-title":"A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus","volume":"89","author":"Yosipovitch","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2175590","DOI":"10.1080\/0886022x.2023.2175590","article-title":"Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients","volume":"45","author":"Zhang","year":"2023","journal-title":"Ren Fail"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"Cd011393","DOI":"10.1002\/14651858.CD011393.pub2","article-title":"Interventions for itch in people with advanced chronic kidney disease","volume":"2020","author":"Hercz","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.xkme.2022.100513","article-title":"Safety and tolerability of Difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program","volume":"4","author":"Fishbane","year":"2022","journal-title":"Kidney Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence--indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.12669\/pjms.321.8547","article-title":"Comparison of gabapentin and Ketotifen in treatment of uremic pruritus in hemodialysis patients","volume":"32","author":"Amirkhanlou","year":"2016","journal-title":"Pak J Med Sci"},{"key":"ref20","first-page":"38","article-title":"Evaluation of antipruritic effect of melatonin on hemodialysis patients with uremic pruritus, a double-blind, randomized","volume":"1","author":"Baharvand","year":"2021","journal-title":"Crossover Trial Iran J Kidney Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ekir.2020.01.006","article-title":"Randomized controlled trial of Difelikefalin for chronic pruritus in hemodialysis patients","volume":"5","author":"Fishbane","year":"2020","journal-title":"Kidney Int Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s10157-021-02047-2","article-title":"Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study","volume":"25","author":"Kinugasa","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"ref24","first-page":"50","article-title":"Therapeutic effect of Montelukast for treatment of uremic pruritus in hemodialysis patients","volume":"11","author":"Mahmudpour","year":"2017","journal-title":"Iran J Kidney Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000484573","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of Nalbuphine ER tablets for uremic pruritus","volume":"46","author":"Mathur","year":"2017","journal-title":"Am J Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/ced.14270","article-title":"Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis","volume":"45","author":"Mohammadi Kebar","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"ref27","first-page":"378","article-title":"Gabapentin: a promising drug for the treatment of uremic pruritus","volume":"18","author":"Naini","year":"2007","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e2210339","DOI":"10.1001\/jamanetworkopen.2022.10339","article-title":"Efficacy and safety of Difelikefalin in Japanese patients with moderate to severe pruritus receiving hemodialysis: a randomized clinical trial","volume":"5","author":"Narita","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3109\/09546634.2016.1161161","article-title":"Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature","volume":"27","author":"Nofal","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.4103\/1319-2442.118070","article-title":"Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study","volume":"24","author":"Omidian","year":"2013","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4103\/ijpc.Ijpc_212_19","article-title":"Comparison of safety and efficacy of Pregabalin versus gabapentin for the treatment of uremic pruritus in patients with chronic kidney disease on maintenance Haemodialysis","volume":"26","author":"Ravindran","year":"2020","journal-title":"Indian J Palliat Care"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000187978","article-title":"Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial","volume":"67","author":"Silva","year":"1994","journal-title":"Nephron"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"100512","DOI":"10.1016\/j.xkme.2022.100512","article-title":"Efficacy of Difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies","volume":"4","author":"Topf","year":"2022","journal-title":"Kidney Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ndt\/gfp628","article-title":"Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study","volume":"25","author":"Vessal","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1681\/asn.2005020152","article-title":"Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstr\u00f6m","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/cia.S23783","article-title":"Gabapentin for once-daily treatment of post-herpetic neuralgia: a review","volume":"7","author":"Beal","year":"2012","journal-title":"Clin Interv Aging"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ijd.14708","article-title":"Gabapentin for uremic pruritus: a systematic review of randomized controlled trials","volume":"59","author":"Eusebio-Alpapara","year":"2020","journal-title":"Int J Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/08860220802595476","article-title":"Gabapentin and uremic pruritus in hemodialysis patients","volume":"31","author":"Razeghi","year":"2009","journal-title":"Ren Fail"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1049909112445464","article-title":"Gabapentin for pruritus in palliative care","volume":"30","author":"Anand","year":"2013","journal-title":"Am J Hosp Palliat Care"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/mnh.0000000000000625","article-title":"Recent advances in the treatment of uremic pruritus","volume":"29","author":"Trachtenberg","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1542-4758.2006.00093.x","article-title":"Cromolyn sodium: a potential therapy for uremic pruritus?","volume":"10","author":"Rosner","year":"2006","journal-title":"Hemodial Int"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"CD008320","DOI":"10.1002\/14651858.CD008320.pub3","article-title":"Pharmacological interventions for pruritus in adult palliative care patients","volume":"2016","author":"Siemens","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jaad.2015.09.039","article-title":"Thalidomide for the treatment of chronic refractory pruritus","volume":"74","author":"Sharma","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1334944\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:45:06Z","timestamp":1712292306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1334944\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":43,"alternative-id":["10.3389\/fmed.2024.1334944"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1334944","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"article-number":"1334944"}}